These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank? Sharp M; Camp R GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858 [No Abstract] [Full Text] [Related]
9. The optimal use of enfuvirtide. Gallant JE Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103 [No Abstract] [Full Text] [Related]
10. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James. Grossman H AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. Green J; Kleinman L; Ciesla G; Huang J; Wintfeld N; Revicki D HIV Clin Trials; 2002; 3(5):387-95. PubMed ID: 12407488 [TBL] [Abstract][Full Text] [Related]
12. Three new drugs approved by FDA. Hoyt G Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579 [No Abstract] [Full Text] [Related]
13. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. Cohen CJ; Dusek A; Green J; Johns EL; Nelson E; Recny MA AIDS Patient Care STDS; 2002 Jul; 16(7):327-35. PubMed ID: 12194730 [TBL] [Abstract][Full Text] [Related]
14. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection. Polk C; Chan-Tack KM; Kopack AM; Amoroso A AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655 [No Abstract] [Full Text] [Related]
15. [HIV infections: further options for combination therapy]. Hildegard K Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165 [No Abstract] [Full Text] [Related]
16. Enfuvirtide access, administration, and patient education. Celano SA Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102 [No Abstract] [Full Text] [Related]
18. Long path to approval. A look back at the road to Fuzeon. GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856 [No Abstract] [Full Text] [Related]
19. T-20 being called "miraculous". AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581 [No Abstract] [Full Text] [Related]
20. New-Fill on "hold" and open-label for T-20. Berger DS Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532 [No Abstract] [Full Text] [Related] [Next] [New Search]